Which clinical history findings are characteristic of Langerhans cell histiocytosis (LCH)?

1. Komp DM. Historical perspectives of Langerhans cell histiocytosis. Hematol Oncol Clin North Am. 1987 Mar. 1(1):9-21. [Medline].

2. Merad M, Ginhoux F, Collin M. Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells. Nat Rev Immunol. 2008 Dec. 8(12):935-47. [Medline].

3. Egeler RM, van Halteren AG, Hogendoorn PC, Laman JD, Leenen PJ. Langerhans cell histiocytosis: fascinating dynamics of the dendritic cell-macrophage lineage. Immunol Rev. 2010 Mar. 234(1):213-32. [Medline].

4. Satter EK, High WA. Langerhans cell histiocytosis: a review of the current recommendations of the Histiocyte Society. Pediatr Dermatol. 2008 May-Jun. 25(3):291-5. [Medline].

5. Emile JF, Abla O, Fraitag S, et al. Revised classification of histiocytoses and neoplasms of the macrophage-dendritic cell lineages. Blood. 2016 Jun 2. 127 (22):2672-81. [Medline].

6. Egeler RM, Favara BE, van Meurs M, Laman JD, Claassen E. Differential In situ cytokine profiles of Langerhans-like cells and T cells in Langerhans cell histiocytosis: abundant expression of cytokines relevant to disease and treatment. Blood. 1999 Dec 15. 94(12):4195-201. [Medline].

7. da Costa CE, Szuhai K, van Eijk R, et al. No genomic aberrations in Langerhans cell histiocytosis as assessed by diverse molecular technologies. Genes Chromosomes Cancer. 2009 Mar. 48(3):239-49. [Medline].

8. Willman CL. Detection of clonal histiocytes in Langerhans cell histiocytosis: biology and clinical significance. Br J Cancer Suppl. 1994 Sep. 23:S29-33. [Medline].

9. Willman CL, Busque L, Griffith BB, et al. Langerhans'-cell histiocytosis (histiocytosis X)--a clonal proliferative disease. N Engl J Med. 1994 Jul 21. 331(3):154-60. [Medline].

10. Berres ML, Lim KP, Peters T, Price J, Takizawa H, Salmon H, et al. BRAF-V600E expression in precursor versus differentiated dendritic cells defines clinically distinct LCH risk groups. J Exp Med. 2014 Apr 7. 211 (4):669-83. [Medline].

11. Chakraborty R, Hampton OA, Shen X, et al. Mutually exclusive recurrent somatic mutations in MAP2K1 and BRAF support a central role for ERK activation in LCH pathogenesis. Blood. 2014 Nov 6. 124 (19):3007-15. [Medline].

12. Mitchell J, Kelly J, Kvedaraite E, et al. Foxp3⁺ Tregs from Langerhans cell histiocytosis lesions co-express CD56 and have a definitively regulatory capacity. Clin Immunol. 2020 Apr 10. 215:108418. [Medline].

13. Allen CE, Li L, Peters TL, Leung HC, Yu A, Man TK. Cell-specific gene expression in Langerhans cell histiocytosis lesions reveals a distinct profile compared with epidermal Langerhans cells. J Immunol. 2010 Apr 15. 184(8):4557-67. [Medline].

14. Senechal B, Elain G, Jeziorski E, Grondin V, Patey-Mariaud de Serre N, Jaubert F. Expansion of regulatory T cells in patients with Langerhans cell histiocytosis. PLoS Med. 2007 Aug. 4(8):e253. [Medline].

15. Coury F, Annels N, Rivollier A, et al. Langerhans cell histiocytosis reveals a new IL-17A-dependent pathway of dendritic cell fusion. Nat Med. 2008 Jan. 14(1):81-7. [Medline].

16. Allen CE, McClain KL. Interleukin-17A is not expressed by CD207(+) cells in Langerhans cell histiocytosis lesions. Nat Med. 2009 May. 15(5):483-4; author reply 484-5. [Medline]. [Full Text].

17. Bank MI, Gudbrand C, Rengtved P, et al. Immunohistochemical detection of the apoptosis-related proteins FADD, FLICE, and FLIP in Langerhans cell histiocytosis. J Pediatr Hematol Oncol. 2005 Jun. 27(6):301-6. [Medline].

18. Dina A, Zahava V, Iness M. The role of vascular endothelial growth factor in Langerhans cell histiocytosis. J Pediatr Hematol Oncol. 2005 Feb. 27(2):62-6. [Medline].

19. Marchal J, Kambouchner M, Tazi A, Valeyre D, Soler P. Expression of apoptosis-regulatory proteins in lesions of pulmonary Langerhans cell histiocytosis. Histopathology. 2004 Jul. 45(1):20-8. [Medline].

20. Battistella M, Fraitag S, Teillac DH, Brousse N, de Prost Y, Bodemer C. Neonatal and early infantile cutaneous langerhans cell histiocytosis: comparison of self-regressive and non-self-regressive forms. Arch Dermatol. 2010 Feb. 146(2):149-56. [Medline].

21. Lonardi S, Scutera S, Licini S, Lorenzi L, Cesinaro AM, Benerini Gatta L, et al. CSF1R is required for differentiation and migration of Langerhans cells and Langerhans cell histiocytosis. Cancer Immunol Res. 2020 Apr 1. [Medline].

22. Andersson By U, Tani E, Andersson U, Henter JI. Tumor necrosis factor, interleukin 11, and leukemia inhibitory factor produced by Langerhans cells in Langerhans cell histiocytosis. J Pediatr Hematol Oncol. 2004 Nov. 26(11):706-11. [Medline].

23. Kawakubo Y, Kishimoto H, Sato Y, et al. Human cytomegalovirus infection in foci of Langerhans cell histiocytosis. Virchows Arch. 1999 Feb. 434(2):109-15. [Medline].

24. Kannourakis G, Abbas A. The role of cytokines in the pathogenesis of Langerhans cell histiocytosis. Br J Cancer Suppl. 1994 Sep. 23:S37-40. [Medline].

25. Csire M, Mikala G, Jako J, Masszi T, Janosi J, Dolgos J. Persistent long-term human herpesvirus 6 (HHV-6) infection in a patient with langerhans cell histiocytosis. Pathol Oncol Res. 2007. 13(2):157-60. [Medline].

26. Strenger V, Urban C. Chromosomal integration of the HHV-6 genome as a possible cause of persistent HHV-6 detection in a patient with langerhans cell histiocytosis. Pathol Oncol Res. 2010 Mar. 16(1):125-6. [Medline].

27. Liu H, Osterburg AR, Flury J, et al. MAPK mutations and cigarette smoke promote the pathogenesis of pulmonary Langerhans cell histiocytosis. JCI Insight. 2020 Feb 27. 5 (4):[Medline].

28. Windebank KP, Nanduri V. Langerhans Cell Histiocytosis. Arch Dis Child. 2009 May 19. [Medline].

29. Wolters PJ, Elicker BM. Subacute onset of pulmonary langerhans cell histiocytosis with resolution after smoking cessation. Am J Respir Crit Care Med. 2014 Dec 1. 190 (11):e64. [Medline].

30. Vassallo R, Harari S, Tazi A. Current understanding and management of pulmonary Langerhans cell histiocytosis. Thorax. 2017 Oct. 72 (10):937-945. [Medline].

31. Lahey E. Histiocytosis x--an analysis of prognostic factors. J Pediatr. 1975 Aug. 87(2):184-9. [Medline].

32. Gadner H, Grois N, Arico M, et al. A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr. 2001 May. 138(5):728-34. [Medline].

33. Nann D, Schneckenburger P, Steinhilber J, et al. Pediatric Langerhans cell histiocytosis: the impact of mutational profile on clinical progression and late sequelae. Ann Hematol. 2019 Jul. 98 (7):1617-1626. [Medline].

34. Ozer E, Sevinc A, Ince D, Yuzuguldu R, Olgun N. BRAF V600E Mutation: A Significant Biomarker for Prediction of Disease Relapse in Pediatric Langerhans Cell Histiocytosis. Pediatr Dev Pathol. 2019 Oct. 22 (5):449-455. [Medline].

35. Cui L, Zhang L, Ma HH, et el. Circulating cell-free BRAFV600E during chemotherapy is associated with prognosis of children with Langerhans cell histiocytosis. Haematologica. 2020 Jan 9. [Medline].

36. Visser J, Hutter C, Sieni E, et al. Vemurafenib for Refractory Multisystem Langerhans Cell Histiocytosis in Children: An International Observational Study. J Clin Oncol. 2019 Nov 1. 37 (31):2857-2865. [Medline].

37. Minkov M, Prosch H, Steiner M, et al. Langerhans cell histiocytosis in neonates. Pediatr Blood Cancer. 2005 Nov. 45(6):802-7. [Medline].

38. Shaffer MP, Walling HW, Stone MS. Langerhans cell histiocytosis presenting as blueberry muffin baby. J Am Acad Dermatol. 2005 Aug. 53(2 Suppl 1):S143-6. [Medline].

39. Hwang C, Kim YJ, Seo YJ, Park JK, Lee JH, Lee Y. Isolated langerhans cell histiocytosis of the vulva in an infant. Pediatr Dermatol. 2009 Nov-Dec. 26(6):751-3. [Medline].

40. Lin MW, Chang YL, Lee YC, Cheng HL, Chen JS, Hsu HH. Pulmonary Langerhans cell histiocytosis. Lung. 2009 Aug. 187(4):261-2. [Medline].

41. Shima H, Takahashi T, Shimada H. Protein-losing enteropathy caused by gastrointestinal tract-involved Langerhans cell histiocytosis. Pediatrics. 2010 Feb. 125(2):e426-32. [Medline].

42. Uchiyama M, Watanabe R, Ito I, Ikeda T. Thyroid involvement in pulmonary langerhans cell histiocytosis. Intern Med. 2009. 48(23):2047-8. [Medline].

43. Kluge G, Sorge I, Bierbach U, Hirsch W. Scapula as an uncommon site of Langerhans cell histiocytosis in an infant. Pediatr Int. 2010 Feb. 52(1):142-4. [Medline].

44. Cunningham MJ, Curtin HD, Jaffe R, Stool SE. Otologic manifestations of Langerhans' cell histiocytosis. Arch Otolaryngol Head Neck Surg. 1989 Jul. 115(7):807-13. [Medline].

45. Callebaut W, Demedts M, Verleden G. Pulmonary Langerhans' cell granulomatosis (histiocytosis X): clinical analysis of 8 cases. Acta Clin Belg. 1998 Oct. 53(5):337-43. [Medline].

46. Okten A, Mocan H, Erduran E, Aslan Y, Gumele HR, Ozoran Y. Langerhans cell histiocytosis associated with recurrent pneumothorax: a case report. Turk J Pediatr. 1996 Jan-Mar. 38(1):125-30. [Medline].

47. Haupt R, Nanduri V, Calevo MG, et al. Permanent consequences in Langerhans cell histiocytosis patients: a pilot study from the Histiocyte Society-Late Effects Study Group. Pediatr Blood Cancer. 2004 May. 42(5):438-44. [Medline].

48. Vrijmoet-Wiersma CM, Kooloos VM, Koopman HM, et al. Health-related quality of life, cognitive functioning and behaviour problems in children with Langerhans cell histiocytosis. Pediatr Blood Cancer. 2009 Jan. 52(1):116-22. [Medline].

49. Dunger DB, Broadbent V, Yeoman E, et al. The frequency and natural history of diabetes insipidus in children with Langerhans-cell histiocytosis. N Engl J Med. 1989 Oct 26. 321(17):1157-62. [Medline].

50. Grois N, Potschger U, Prosch H, et al. Risk factors for diabetes insipidus in langerhans cell histiocytosis. Pediatr Blood Cancer. 2006 Feb. 46(2):228-33. [Medline].

51. Abla O, Weitzman S, Minkov M, et al. Diabetes insipidus in Langerhans cell histiocytosis: When is treatment indicated?. Pediatr Blood Cancer. 2009 May. 52(5):555-6. [Medline].

52. Weitzman S, Egeler RM. Langerhans cell histiocytosis: update for the pediatrician. Curr Opin Pediatr. 2008 Feb. 20(1):23-9. [Medline].

53. Billings TL, Barr R, Dyson S. Langerhans cell histiocytosis mimicking malignant melanoma: a diagnostic pitfall. Am J Dermatopathol. 2008 Oct. 30(5):497-9. [Medline].

54. Calming U, Henter JI. Elevated erythrocyte sedimentation rate and thrombocytosis as possible indicators of active disease in Langerhans' cell histiocytosis. Acta Paediatr. 1998 Oct. 87(10):1085-7. [Medline].

55. Steiner M, Prayer D, Asenbaum S, et al. Modern imaging methods for the assessment of Langerhans' cell histiocytosis-associated neurodegenerative syndrome: case report. J Child Neurol. 2005 Mar. 20(3):253-7. [Medline].

56. Phillips M, Allen C, Gerson P, McClain K. Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2009 Jan. 52(1):97-101. [Medline].

57. Derenzini E, Fina MP, Stefoni V, Pellegrini C, Venturini F, Broccoli A. MACOP-B regimen in the treatment of adult Langerhans cell histiocytosis: experience on seven patients. Ann Oncol. 2009 Oct 27. [Medline].

58. Nanduri V, Tatevossian R, Sirimanna T. High incidence of hearing loss in long-term survivors of multisystem Langerhans cell histiocytosis. Pediatr Blood Cancer. 2010 Mar. 54(3):449-53. [Medline].

59. Gavhed D, Akefeldt SO, Osterlundh G, Laurencikas E, Hjorth L, Blennow K. Biomarkers in the cerebrospinal fluid and neurodegeneration in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2009 Dec 15. 53(7):1264-70. [Medline].

60. Favara BE, Feller AC, Pauli M, et al. Contemporary classification of histiocytic disorders. The WHO Committee On Histiocytic/Reticulum Cell Proliferations. Reclassification Working Group of the Histiocyte Society. Med Pediatr Oncol. 1997 Sep. 29(3):157-66. [Medline].

61. Valladeau J, Ravel O, Dezutter-Dambuyant C, et al. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. Immunity. 2000 Jan. 12(1):71-81. [Medline].

62. Gadner H. Treatment of adult-onset Langerhans cell histiocytosis--is it different from the pediatric approach?. Ann Oncol. 2009 Nov 25. [Medline].

63. Montella L, Merola C, Merola G, Petillo L, Palmieri G. Zoledronic acid in treatment of bone lesions by Langerhans cell histiocytosis. J Bone Miner Metab. 2009. 27(1):110-3. [Medline].

64. Munn SE, Olliver L, Broadbent V, Pritchard J. Use of indomethacin in Langerhans cell histiocytosis. Med Pediatr Oncol. 1999 Apr. 32(4):247-9. [Medline].

65. Goldberg SA, O'Connor SC, Sprinz PG. Prostaglandin inhibitors in the treatment of single-system Langerhans cell histiocytosis: pharmacologic rationale and report of two cases. J Pediatr Hematol Oncol. 2008 Oct. 30(10):778-80. [Medline].

66. Cardoso JC, Cravo M, Cardoso R, Brites MM, Reis JP, Tellechea O. Langerhans cell histiocytosis in an adult: good response of cutaneous lesions to acitretin. Clin Exp Dermatol. 2010 Feb 22. [Medline].

67. Sakai H, Ibe M, Takahashi H, et al. Satisfactory remission achieved by PUVA therapy in Langerhans cell hisiocytosis in an elderly patient. J Dermatol. 1996 Jan. 23(1):42-6. [Medline].

68. Vogel CA, Aughenbaugh W, Sharata H. Excimer laser as adjuvant therapy for adult cutaneous Langerhans cell histiocytosis. Arch Dermatol. 2008 Oct. 144(10):1287-90. [Medline].

69. Lazor R, Etienne-Mastroianni B, Khouatra C, Tazi A, Cottin V, Cordier JF. Progressive diffuse pulmonary Langerhans cell histiocytosis improved by cladribine chemotherapy. Thorax. 2009 Mar. 64(3):274-5. [Medline].

70. Néel A, Artifoni M, Fontenoy AM, et al. Long-term efficacy and safety of 2CdA (cladribine) in extra-pulmonary adult-onset Langerhans cell histiocytosis: analysis of 23 cases from the French Histiocytosis Group and systematic literature review. Br J Haematol. 2020 Mar 19. [Medline].

71. Gadner H, Heitger A, Grois N, Gatterer-Menz I, Ladisch S. Treatment strategy for disseminated Langerhans cell histiocytosis. DAL HX-83 Study Group. Med Pediatr Oncol. 1994. 23(2):72-80. [Medline].

72. Gadner H, Grois N, Potschger U, et al. Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 2008 Mar 1. 111(5):2556-62. [Medline].

73. Weitzman S, Braier J, Donadieu J, Egeler RM, Grois N, Ladisch S. 2'-Chlorodeoxyadenosine (2-CdA) as salvage therapy for Langerhans cell histiocytosis (LCH). results of the LCH-S-98 protocol of the Histiocyte Society. Pediatr Blood Cancer. 2009 Dec 15. 53(7):1271-6. [Medline].

74. Donadieu J, Bernard F, van Noesel M, Barkaoui M, Bardet O, Mura R, et al. Cladribine and cytarabine in refractory multisystem Langerhans cell histiocytosis: results of an international phase 2 study. Blood. 2015 Sep 17. 126 (12):1415-23. [Medline].

75. Imamura T, Sato T, Shiota Y, et al. Outcome of pediatric patients with Langerhans cell histiocytosis treated with 2 chlorodeoxyadenosine: a nationwide survey in Japan. Int J Hematol. 2010 May. 91(4):646-51. [Medline].

76. Conter V, Reciputo A, Arrigo C, Bozzato N, Sala A, Aricò M. Bone marrow transplantation for refractory Langerhans' cell histiocytosis. Haematologica. 1996 Sep-Oct. 81(5):468-71. [Medline].

77. Steiner M, Matthes-Martin S, Attarbaschi A, et al. Improved outcome of treatment-resistant high-risk Langerhans cell histiocytosis after allogeneic stem cell transplantation with reduced-intensity conditioning. Bone Marrow Transplant. 2005 Aug. 36(3):215-25. [Medline].

78. Kesik V, Citak C, Kismet E, Koseoglu V, Akyuz C. Hematopoietic stem cell transplantation in Langerhans cell histiocytosis: case report and review of the literature. Pediatr Transplant. 2009 May. 13(3):371-4. [Medline].

79. Veys PA, Nanduri V, Baker KS, et al. Haematopoietic stem cell transplantation for refractory Langerhans cell histiocytosis: outcome by intensity of conditioning. Br J Haematol. 2015 Jun. 169 (5):711-8. [Medline].

80. Kudo K, Ohga S, Morimoto A, Ishida Y, Suzuki N, Hasegawa D. Improved outcome of refractory Langerhans cell histiocytosis in children with hematopoietic stem cell transplantation in Japan. Bone Marrow Transplant. 2009 Sep 21. [Medline].

81. McClain KL, Kozinetz CA. A phase II trial using thalidomide for Langerhans cell histiocytosis. Pediatr Blood Cancer. 2007 Jan. 48(1):44-9. [Medline].

82. Badalian-Very G, Vergilio JA, Degar BA, MacConaill LE, Brandner B, Calicchio ML, et al. Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood. September 2010. 116:1919-23. [Medline].

83. Haroche J, Cohen-Aubart F, Emile JF, Arnaud L, Maksud P, Charlotte F, et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood. 2013 Feb 28. 121 (9):1495-500. [Medline].

84. Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, et al. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015 Aug 20. 373 (8):726-36. [Medline]. [Full Text].

85. Zelboraf (vemurafenib) [package insert]. South San Francisco, Calif: Genentech. November 6, 2017. Available at [Full Text].

86. Diamond EL, Subbiah V, Lockhart AC, et al. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. JAMA Oncol. 2018 Mar 1. 4 (3):384-388. [Medline].

87. Diamond EL, Durham BH, Ulaner GA, et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature. 2019 Mar. 567 (7749):521-524. [Medline].

88. Jordan MB, McClain KL, Yan X, Hicks J, Jaffe R. Anti-CD52 antibody, alemtuzumab, binds to Langerhans cells in Langerhans cell histiocytosis. Pediatr Blood Cancer. 2005 Mar. 44(3):251-4. [Medline].

89. Idbaih A, Donadieu J, Barthez MA, et al. Retinoic acid therapy in "degenerative-like" neuro-langerhans cell histiocytosis: a prospective pilot study. Pediatr Blood Cancer. 2004 Jul. 43(1):55-8. [Medline].

90. Nakajima K, Morisawa R, Kodama H, Sano S. Successful treatment with cyclophosphamide of Langerhans cell histiocytosis involving the skin and lymph nodes in an adult patient. Clin Exp Dermatol. 2010 Mar 19. [Medline].

91. Wagner C, Mohme H, Kromer-Olbrisch T, Stadler R, Goerdt S, Kurzen H. Langerhans cell histiocytosis: treatment failure with imatinib. Arch Dermatol. 2009 Aug. 145(8):949-50. [Medline].

92. Montella L, Insabato L, Palmieri G. Imatinib mesylate for cerebral Langerhans'-cell histiocytosis. N Engl J Med. 2004 Sep 2. 351(10):1034-5. [Medline].

Christopher R Shea, MD Eugene J Van Scott Professor in Dermatology, Chief, Section of Dermatology, Department of Medicine, University of Chicago, The Pritzker School of Medicine

Christopher R Shea, MD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Dermatology, American Society of Dermatopathology, Arthur Purdy Stout Society, Association of Professors of Dermatology, Chicago Dermatological Society, Dermatology Foundation, Illinois Dermatological Society, International Society of Dermatopathology, Society for Investigative Dermatology

Disclosure: Nothing to disclose.

Shay X Huang MD Candidate, The University of Chicago Pritzker School of Medicine

Disclosure: Nothing to disclose.

Richard P Vinson, MD Assistant Clinical Professor, Department of Dermatology, Texas Tech University Health Sciences Center, Paul L Foster School of Medicine; Consulting Staff, Mountain View Dermatology, PA

Richard P Vinson, MD is a member of the following medical societies: American Academy of Dermatology, Texas Medical Association, Association of Military Dermatologists, Texas Dermatological Society

Disclosure: Nothing to disclose.

William D James, MD Paul R Gross Professor of Dermatology, Vice-Chairman, Residency Program Director, Department of Dermatology, University of Pennsylvania School of Medicine

William D James, MD is a member of the following medical societies: American Academy of Dermatology, Society for Investigative Dermatology

Disclosure: Received income in an amount equal to or greater than $250 from: Elsevier; WebMD.

Markus D Boos, MD, PhD Assistant Professor of Pediatrics, University of Washington School of Medicine

Markus D Boos, MD, PhD is a member of the following medical societies: Alpha Omega Alpha, American Academy of Pediatrics

Disclosure: Nothing to disclose.

The authors and editors of Medscape Reference gratefully acknowledge the contributions of previous author, M. Angelica Selim, MD, to the development and writing of this article.